Uterine Leiomyosarcoma.
Journal
Journal of the advanced practitioner in oncology
ISSN: 2150-0878
Titre abrégé: J Adv Pract Oncol
Pays: United States
ID NLM: 101550346
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
entrez:
17
2
2022
pubmed:
18
2
2022
medline:
18
2
2022
Statut:
ppublish
Résumé
Leiomyosarcoma (LMS) is the most common soft tissue sarcoma in adults and can occur in any part of the body. Uterine leiomyosarcoma (uLMS) is the most common location for LMS, making up 2% to 5% of all uterine malignancies. It is an aggressive tumor that is challenging to treat because of its resistance to standard therapy. The majority of patients (60%) are diagnosed with early-stage disease. However, regardless of the stage, uLMS has a poor prognosis. Surgical resection is the cornerstone of treatment for patients with localized LMS independent of the site of origin. Adjuvant chemotherapy for early-stage disease remains controversial as multiple clinical trials have failed to demonstrate benefit on overall survival. Progress has been made in therapy for advanced and recurrent disease. This case study will highlight the current and emerging data regarding novel therapies for women with uLMS.
Identifiants
pubmed: 35173990
doi: 10.6004/jadpro.2022.13.1.6
pii: 2022.13.1.6
pmc: PMC8805803
doi:
Types de publication
Journal Article
Langues
eng
Pagination
70-76Informations de copyright
© 2022 Harborside™.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Gynecol Oncol. 2018 Dec;151(3):562-572
pubmed: 30244960
Chin J Cancer Res. 2017 Dec;29(6):521-532
pubmed: 29353974
J Clin Oncol. 2018 Jan 10;36(2):144-150
pubmed: 29220301
J Gynecol Oncol. 2014 Oct;25(4):306-12
pubmed: 25142630
J Clin Oncol. 2016 Mar 10;34(8):786-93
pubmed: 26371143
Gynecol Oncol. 2012 May;125(2):409-13
pubmed: 22366592
J Clin Oncol. 2015 Apr 1;33(10):1180-5
pubmed: 25713428
Am J Obstet Gynecol. 2014 Mar;210(3):194-9
pubmed: 23942040
J Med Case Rep. 2010 Jul 22;4:222
pubmed: 20649999
Cancer. 2013 Apr 15;119(8):1555-61
pubmed: 23335221
Gynecol Oncol. 2017 Sep;146(3):531-537
pubmed: 28651804
J Gynecol Oncol. 2009 Sep;20(3):135-6
pubmed: 19809545
Int J Gynaecol Obstet. 2009 Mar;104(3):177-8
pubmed: 19135669
Curr Opin Oncol. 2013 Sep;25(5):546-52
pubmed: 23942299
J Clin Oncol. 2016 Jul 1;34(19):2294-302
pubmed: 27185843
Onco Targets Ther. 2019 Oct 16;12:8583-8586
pubmed: 31802894
Crit Rev Oncol Hematol. 2008 Feb;65(2):129-42
pubmed: 17706430
Gynecol Oncol. 2009 Mar;112(3):563-7
pubmed: 19135708